Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer

Eisenhauer, Elizabeth; Pritchard, Kathleen I.; Perrault, D. J.; Verma, Shailendra; Pater, Joseph L.

doi:10.1007/bf00171838

Cited by 7 publications

(3 citation statements)

References 4 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, 3 patients achieved stable disease for > 8 months with documented clinical improvement evidenced by improved performance status, discontinuation of opiates, and decreased use of nonnarcotic analgesics. The drug was well tolerated except for myelotoxicity which was more common and severe in this study than in other menogaril trials at higher doses [5,6]. The responses observed in phase II studies using menogaril have been low with the best responses observed in lymphoma and breast cancer [5,6].…”

Section: Discussionmentioning

confidence: 49%

“…The drug was well tolerated except for myelotoxicity which was more common and severe in this study than in other menogaril trials at higher doses [5,6]. The responses observed in phase II studies using menogaril have been low with the best responses observed in lymphoma and breast cancer [5,6]. The absence of measurable responses in this study may be partially due to the lack of dose intensification since the starting dose was 40 mg/m 2 lower than used in other studies [5,6].…”

Section: Discussionmentioning

confidence: 54%

“…The responses observed in phase II studies using menogaril have been low with the best responses observed in lymphoma and breast cancer [5,6]. The absence of measurable responses in this study may be partially due to the lack of dose intensification since the starting dose was 40 mg/m 2 lower than used in other studies [5,6]. Although higher doses may be more effective, dose escalation in this disease would be risky due to the compromised bone marrow reserve.…”

Section: Discussionmentioning

confidence: 69%

See 2 more Smart Citations

Menogaril in the treatment of relapsed multiple myeloma

Cruz¹,

Case²,

Dalton³

et al. 1992

Invest New Drugs

View full text Add to dashboard Cite

Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Menogaril in the treatment of relapsed multiple myeloma

Cruz¹,

Case²,

Dalton³

et al. 1992

Invest New Drugs

View full text Add to dashboard Cite

show abstract

Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group

Pritchard

1994

Cancer

View full text Add to dashboard Cite

For more than 10 years, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Breast Cancer Site Group has focused primarily on trials of adjuvant therapy and of investigational new drugs (JND). Four trials of adjuvant therapy in node‐positive women have been completed, are active, or are about to begin. Investigational new drug (IND) studies have included Phase II trials of intravenous and oral menagaril, 10‐EDAM (eda‐trexate), taxotere, and mifepristone (RU‐486) as well as a Phase 1/11 trial of 5‐fluorouracil (5‐FU), doxorubicin, and vinorelbine (FAN): a Phase 1/11 trial of 5‐FU, leucovorin, doxorubicin, and vinorelbine (super‐FAN), all as first‐line therapy for metastatic disease; and a Phase III study of vinorelbine plus doxorubicin versus doxorubicin alone as first‐ or second‐line metastatic therapy. A proposed study with the European Organization for Research and Treatment of Cancer in locally advanced breast cancer will compare a standard NCIC CTG regimen of cyclophosphamide, epirubicin, and 5‐FU (CEF) with epirubicin and cyclophosphamide granulocyte colony‐stimulating factor (G‐CSF), a more dose‐intensive regimen. In addition, NCIC CTG is preparing a pilot of CEF with G‐CSF to examine whether a substantially more intensive dosage can be given without added toxicity. NCIC CTG will also enter patients into a currently active Cancer and Leukemia Group B/Southwest Oncology Group randomized trial of intensive therapy versus more intensive therapy with bone marrow support in women younger than age 60 with 10 or more positive nodes. It is believed that optimizing the combination and timing of adjuvant hormonal and chemotherapy, exploring dose intensive approaches, developing investigational new drugs, studying the role of biologics, and tumor banking in conjunction with clinical trials remain important approaches for the future.

show abstract

Human autopsy-tissue distribution of menogaril and its metabolites

Grewaal

Green

Goel

et al. 1993

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

Autopsy-tissues were obtained from eight patients who had last received menogaril (total cumulative dose, 175-1080 mg/m2) intravenously (one patient) or orally (seven patients) from 1 to 285 days prior to death. Tissue samples were assayed for menogaril and its metabolities by high-pressure liquid chromatography. Unchanged menogaril was found only in a single lung-tissue sample from a patient who had died < 24 h after receiving his last treatment. N-Demethylmenogaril was found in two lung-tissue samples and in single samples of the thyroid, lymph node, pancreas, cerebellum, and tumor. The major menogaril metabolite found in human autopsy-tissues was 7-deoxynogarol. The highest 7-deoxynogarol concentrations were found in the large bowel (median, 201 ng/g), liver (median, 183 ng/g), and lung (median, 177 ng/g). The heart ranked as the 9th of 18 organs in median 7-deoxynogarol concentration, after the large bowel, liver, lung, tumor, thyroid, skeletal muscle, adrenal gland, and kidney. The lowest concentrations were detected in brain tissue. Our results suggest that the low degree of cardiac toxicity and the possible pulmonary toxicity of menogaril may be related to relative tissue concentrations of menogaril metabolites. Tumor 7-deoxynogarol concentrations were comparable with those in normal tissues, except that concentrations in intracerebral tumors were higher than those in the normal brain. Tissue 7-deoxynogarol concentrations appeared to be directly related to the cumulative dose and inversely related to the time from the last treatment to death; the value obtained by dividing dose by time correlated (P < 0.05) with tissue 7-deoxynogarol concentrations.

show abstract

Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer

Cited by 7 publications

References 4 publications

Menogaril in the treatment of relapsed multiple myeloma

Menogaril in the treatment of relapsed multiple myeloma

Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group

Human autopsy-tissue distribution of menogaril and its metabolites

Contact Info

Product

Resources

About